ProKidney Corp.
Lauren Hartnett Twiss has a diverse work experience spanning various industries and roles. Lauren is currently working as an Associate Director of HR at ProKidney Corp. Prior to this, they worked at Syneos Health, where they held several positions including Manager of Regional Human Resources, Sr. Employee Relations Specialist, and Employee Relations Specialist. Lauren also served as a Manager of HR Operations, Sr. HR Operations Specialist, HR Operations Specialist, and Talent Sourcing Specialist at Syneos Health. Before joining Syneos Health, they worked at The Madison Square Garden Company as a Human Resources Representative and as a Human Resources Student Associate and Trainee. Additionally, they worked at Restaurant Associates as an Events & Catering Manager, where they managed the catering department, supervised union employees, and coordinated large events. Lauren also has experience as an Internet Marketing Consultant at MasterCard and as a Supply Chain Intern at PepsiCo.
Lauren Hartnett Twiss holds a Bachelor of Business Administration degree in Marketing from James Madison University, which they obtained in 2011. In 2013, they pursued a Master of Business Administration (MBA) in Human Resources Management/Personnel Administration, General from Iona University, completing the program in 2014. Lauren also studied Global Marketing at Bahcesehir University in 2011. In 2016, Lauren obtained a Black Belt Certificate from Social Talent, and in 2017, they earned a Professional in Human Resources (PHR) certification from the HR Certification Institute - HRCI.
This person is not in any offices
ProKidney Corp.
ProKidney (Nasdaq: PROK), a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney function. Late-stage CKD, Stage 3b - 4, is a key target for REACT™ therapy. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022. For more information, visit www.prokidney.com.